With an eye on the oncology space, Israeli startup Medial EarlySign has inked a deal with pharma giant Roche Diagnostics International to commercialize an artificial intelligence tool that helps detect cancer early. As part of the collaboration agreement, the pair will develop, clinically validate and then commercialize the product.
Initially the companies will focus on the gastric cancer space...
Israeli remote care automation company, Datos Health has announced a collaboration with AI-based clinical insights provider, Medial EarlySign to offer an integrated platform that identifies high-risk patients who would benefit from remote care programmes.
WHY IT MATTERS
Combining both companies' core technologies, the partnership aims to help providers achieve better outcomes in vulnerable...
A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.
“The implementation of machine-learning based algorithms to risk stratify populations at risk is commonly feared by many clinicians...
